cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mink Therapeutics Inc
17 own
3 watching
Current Price
$0.89
$0.02
(2.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
49.2M
52-Week High
52-Week High
3.34000
52-Week Low
52-Week Low
0.75000
Average Volume
Average Volume
0.04M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization49.2M
icon52-Week High3.34000
icon52-Week Low0.75000
iconAverage Volume0.04M
iconDividend Yield--
iconP/E Ratio--
What does the Mink Therapeutics Inc do?
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Read More
How much money does Mink Therapeutics Inc make?
News & Events about Mink Therapeutics Inc.
Zolmax
10 months ago
Prime Medicine (NYSE:PRME Get Rating) and MiNK Therapeutics (NASDAQ:INKT Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends...
Ticker Report
10 months ago
Prime Medicine (NYSE:PRME Get Rating) and MiNK Therapeutics (NASDAQ:INKT Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ...
Globe Newswire
1 year ago
Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.In a patient with metastatic gastric cancer who had no response to treatment with pembrolizumab and nivolumab/FOLFOX, agenT-797 induced a partial ...
Ticker Report
1 year ago
MiNK Therapeutics (NASDAQ:INKT Get Rating) had its price target reduced by stock analysts at Evercore ISI from $4.00 to $3.00 in a research report issued to clients and investors on Wednesday, The Fly reports. The firm presently has an outperform rating on the stock. Evercore ...
Globe Newswire
1 year ago
Clinical update of allo-iNKTs (agenT-797) in solid tumors to be presented at AACR Annual Meeting in April 2023AgenT-797 in combination with pembro or nivo in NSCLC and gastric cancer to initiate in 2023Allogeneic CAR platform demonstrates differentiation with IL-15-FAP-CAR-iNKT (MiNK-215) and IL-15-...
Frequently Asked Questions
Frequently Asked Questions
What is Mink Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Mink Therapeutics Inc shares?
plus_minus_icon
How can I buy Mink Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Mink Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Mink Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Mink Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Mink Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Mink Therapeutics Inc?
plus_minus_icon
What percentage is Mink Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Mink Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.89
$0.02
(2.07%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00